TROG 99.06 - Bladder (Phase II) - TROG Cancer Research

By w.paterson
14 August, 2021
0 Comments

Phase I/II Study of Trans-Urethral Resection Followed by Modified Synchronous Chemo-Radiation in the Definitive Management of Localised Invasive TCC of the Urinary Bladder

Primary Sponsor

Tour de Cure grants for TROG Cancer Research trials

9 January, 2025

Tour de Cure grants support two valuable TROG trials

9 January 2025: Two important TROG Cancer Research trials

7 January, 2025

GenesisCare Foundation $300,000 donation to support TROG work

7 January 2025: TROG Cancer Research is advancing vital

Earlybird registration closes 26 January.

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

Phase I/II Study of Trans-Urethral Resection Followed by Modified Synchronous Chemo-Radiation in the Definitive Management of Localised Invasive TCC of the Urinary Bladder

EORTC 22996-24002/TROG 01.01 – EPO Head & Neck

TROG 99.05 – Lung Tumour Volume

Related Post

Tour de Cure grants support two valuable TROG trials

GenesisCare Foundation $300,000 donation to support TROG work

TROG 99.06 – Bladder (Phase II)

Phase I/II Study of Trans-Urethral Resection Followed by Modified Synchronous Chemo-Radiation in the Definitive Management of Localised Invasive TCC of the Urinary Bladder

EORTC 22996-24002/TROG 01.01 – EPO Head & Neck

TROG 99.05 – Lung Tumour Volume

Related Post

Tour de Cure grants support two valuable TROG trials

GenesisCare Foundation $300,000 donation to support TROG work